Northland Securities Forecasts TLSI FY2025 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Research analysts at Northland Securities issued their FY2025 earnings per share (EPS) estimates for TriSalus Life Sciences in a report issued on Monday, March 2nd. Northland Securities analyst C. Byrnes anticipates that the company will post earnings per share of ($0.85) for the year. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

Several other brokerages have also recently issued reports on TLSI. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group lifted their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Wall Street Zen lowered shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Finally, Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.00.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $4.94 on Wednesday. The stock has a market capitalization of $247.30 million, a price-to-earnings ratio of -2.45 and a beta of 0.42. The business has a 50-day moving average of $5.50 and a 200 day moving average of $5.37. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95.

Hedge Funds Weigh In On TriSalus Life Sciences

Several hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC purchased a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $10,900,000. AWM Investment Company Inc. purchased a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at $6,812,000. Vanguard Group Inc. raised its stake in TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after acquiring an additional 345,186 shares in the last quarter. Gilder Gagnon Howe & Co. LLC lifted its position in TriSalus Life Sciences by 32.1% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after acquiring an additional 265,618 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in TriSalus Life Sciences by 107.4% in the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after acquiring an additional 235,627 shares during the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.